• Vaccine Name: NYVAC-SIV
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004779
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001093
  • Description: (Benson et al., 1998)
• Preparation: The gag, pol, and env genes of SIV(K6W) were expressed in the NYVAC vector (Benson et al., 1998).
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccination Protocol: The macaques were immunized with NYVAC-SIV and NYVAC-IL-12 or NYVAC-SIV alone (Benson et al., 1998).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: At the end of the immunization regimen, half of the animals were challenged with SIV(mac251) by the intravenous route and the other half were exposed to SIV(mac251) intrarectally (Benson et al., 1998).
• Efficacy: Significantly, five of the eleven vaccinees exposed mucosally to SIV(mac251) showed a transient peak of viremia 1 week after viral challenge and subsequently appeared to clear viral infection. In contrast, all 12 animals inoculated intravenously became infected, but 5 to 6 months after viral challenge, 4 animals were able to control viral expression and appeared to progress to disease more slowly than control animals. Protection did not appear to be associated with any of the measured immunological parameters. Further modulation of immune responses by coadministration of NYVAC-cytokine recombinants did not appear to influence the outcome of viral challenge (Benson et al., 1998).